CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro de Atención Médica dedicado a la conducción de Estudios de Investigación Clínica en diferentes fases de desarrollo con más de 10 años de experiencia en diversas áreas de especialización.Av. Pueyrredón 1746 2° A, C1119 Cdad. Autónoma de Buenos Aires, Argentina
Websitehttp://www.ciprec.org/es
Select an option
I am a doctor
I am a sponsor
Specializations
Diabetes
Gastroparesia diabética
Obesidad
Colangitis biliar primaria
Cardiovascular
Enfermedad renal crónica
Hígado graso
Covid-19
Our team
Medical staff
Eliana Serrano
Fernando Guerlloy
Irene Copati
Agustina Bandoni
Agustina Filograsso
Evelyn Garre
Lucia Rey
Vanesa Espinosa
Angela Romero Zarante
César Javier Zaidman
Fernando Gruz
Ezequiel Slutsky
Pablo Olivera Sendra
Noelia Broqua
Tania Zarowsky
Mariano Gabriel Marini
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy - CAMBRIA-1 - AstraZenecaSee more
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZenecaSee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight - MARITIME-1 - AmgenSee more
Arterial hypertension
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - BaxDuo-Arctic - AstraZenecaSee more
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and CompanySee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Renal disease
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - BaxDuo-Arctic - AstraZenecaSee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Cirrhosis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Dermatitis
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) - DUPLEX-AD - Janssen Research & Development, LLCSee more
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Psoriasis
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis - ICONIC-ASCEND - Janssen Research & Development, LLCSee more
